OBJECTIVE: The objective of this systematic review is to determine whether or not bimatoprost 0.03% improves satisfaction in patients at least 12 years old with eyelash hypotrichosis. STUDY DESIGN: Systematic review of three multicenter, double-masked, randomized, parallel group studies, all published in English between 2015 and 2016. DATA SOURCES: All three studies used in this review were researched via PubMed and were published in peer-reviewed journals. OUTCOMES MEASURED: Patient satisfaction was measured using the Eyelash Satisfaction Questionnaire (ESQ) in all three studies. RESULTS: Wirta et al. (J Clin Aesthet Dermatol. 2015;8:11–20.) found a statistically significant relationship between bimatoprost 0.03% and satisfaction with a p=...
OBJECTIVE: The objective of this systematic review is to determine whether or not 5% Imiquimod is mo...
Background: Alopecia areata is an autoimmune disorder causing patchy hair loss on scalp and other pa...
Tomoaki Higashiyama, Masahito Ohji Department of Ophthalmology, Shiga University of Medical Science...
OBJECTIVE: The objective of this systematic review is to determine whether or not bimatoprost 0.03% ...
BACKGROUND: Bimatoprost ophthalmic solution 0.03% is approved in several countries for treating eyel...
Steven FagienAesthetic Eyelid Plastic Surgery, Boca Raton, FL, USAAbstract: Prominent eyelashes are ...
Mark Borchert,1 Suzanne Bruce,2 David Wirta,3 Steven G Yoelin,4 Sungwook Lee,5 Cheri Mao,5 Amanda Va...
Background Bimatoprost 0.03 % has enhanced eyelash prominence in clinical trials enrolling mostly Ca...
PURPOSE: To investigate the efficacy of reducing the drop-skin contact to prevent dermatologic side ...
In December 2008, bimatoprost ophthalmic solution 0.03% was approved in the United States for the tr...
Nongsak Chanasumon, Tueboon Sriphojanart, Poonkiat Suchonwanit Division of Dermatology, Department ...
Background: Patient-reported outcome (PRO) measures have been used to assess treatment benefit in a ...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not topical eflorni...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 2% pirenzepine ...
OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of a fixed combination of b...
OBJECTIVE: The objective of this systematic review is to determine whether or not 5% Imiquimod is mo...
Background: Alopecia areata is an autoimmune disorder causing patchy hair loss on scalp and other pa...
Tomoaki Higashiyama, Masahito Ohji Department of Ophthalmology, Shiga University of Medical Science...
OBJECTIVE: The objective of this systematic review is to determine whether or not bimatoprost 0.03% ...
BACKGROUND: Bimatoprost ophthalmic solution 0.03% is approved in several countries for treating eyel...
Steven FagienAesthetic Eyelid Plastic Surgery, Boca Raton, FL, USAAbstract: Prominent eyelashes are ...
Mark Borchert,1 Suzanne Bruce,2 David Wirta,3 Steven G Yoelin,4 Sungwook Lee,5 Cheri Mao,5 Amanda Va...
Background Bimatoprost 0.03 % has enhanced eyelash prominence in clinical trials enrolling mostly Ca...
PURPOSE: To investigate the efficacy of reducing the drop-skin contact to prevent dermatologic side ...
In December 2008, bimatoprost ophthalmic solution 0.03% was approved in the United States for the tr...
Nongsak Chanasumon, Tueboon Sriphojanart, Poonkiat Suchonwanit Division of Dermatology, Department ...
Background: Patient-reported outcome (PRO) measures have been used to assess treatment benefit in a ...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not topical eflorni...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 2% pirenzepine ...
OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of a fixed combination of b...
OBJECTIVE: The objective of this systematic review is to determine whether or not 5% Imiquimod is mo...
Background: Alopecia areata is an autoimmune disorder causing patchy hair loss on scalp and other pa...
Tomoaki Higashiyama, Masahito Ohji Department of Ophthalmology, Shiga University of Medical Science...